← All trials
NCT05977400
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2024
- Primary completion
- Mar 31, 2029
- Completion date
- Mar 31, 2029
- First posted
- Aug 4, 2023
- Last posted
- Aug 4, 2023
- Enrollment
- 802
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sharp HealthCareLead sponsor
- University of PennsylvaniaCollaborator
- University of PittsburghCollaborator
- Sharp HealthCareOverall official - principal investigator
- Sharp HealthCareReponsible party - principal investigator
- Thomas Jefferson UniversityCollaborator
- University of LouisvilleCollaborator
- University of South FloridaCollaborator
- University of TorontoCollaborator
- Yale UniversityCollaborator
- Pennsylvania State UniversityCollaborator
- State University of New York, BrooklynCollaborator
- University of Texas, San AntonioCollaborator
- New York Presbyterian HospitalCollaborator
- Westchester Medical CenterCollaborator
- Sharp Mary Birch Hospital for Women & Newborns, San Diego, CACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.